Table 1. Characteristics of Included Studies.
| Source (country or region) | Design | Sample size | Ivermectin dose | Comparator | Origin of data | Strongyloidiasis prevalence, % | Corticosteroid use |
|---|---|---|---|---|---|---|---|
| Abd-Elsalam et al,29 2021 (Egypt) | RCT | 164 | 12 mg/d for 3 d | SOC | Published in PR journal | 4.94 | As indicated per Egyptian Ministry of Health SOC |
| Szente Fonseca et al,30 2020 (North Brazil) | Double-blind | 167 | 14 mg/d for 3 d (plus placebo for 2 d) | Hydroxychloroquine, 400 mg BID, on day 0 then daily for 4 d; chloroquine, 450 mg BID on day 0 then daily for 4 d | Published in PR journal | 5.31 | 97% in experimental group, 98%-100% in control group |
| Gonzalez et al,31 2021 (Mexico) | Double-blind | 73 | 12 mg once | Placebo | medRxiv preprint | 7.04 | 58.3% in experimental group, 51.3% in control group |
| Hashim et al,32 2020 (Iran) | Quasi-RCT | 140 | 0.2 mg/kg for 2 d with or without third dose 1 wk later | SOC | Published in PR journal | 5.34 | Dexamethasone, 6 mg/d, or methylprednisolone, 40 mg BID, if indicated |
| I-TECH,17 2021 (Malaysia) | RCT | 490 | 0.4 mg/kg daily for 5 d | SOC | Preliminary report by Ministry of Health of Malaysia | 15.94 | 26.9% in experimental group, 26.5% in control group |
| López-Medina et al,33 2021 (Colombia) | Double-blind | 398 | 0.3 mg/kg for 5 d | Placebo | Published in PR journal | 18.44 | 3% in experimental group, 6.1% in control group |
| Mahmud et al,34 2021 (Bangladesh) | Double-blind | 366 | 12 mg in single dose | Placebo plus SOC | Published in PR journal | 17.34 | As indicated per local SOC guidelines |
| Okumuş et al,35 2021 (Turkey) | RCT | 66 | 0.2 mg/kg for 5 d | SOC | Published in PR journal | 5.64 | Unknown |
| Ravikirti et al,36 2021 (India) | Double-blind | 112 | 12 mg for 2 d plus SOC | Placebo plus SOC | Published in PR journal | 10.44 | All patients received at least 1 dose |
| Shahbaznejad et al,37 2021 (Iran) | Double-blind | 69 | 0.2 mg/kg for 1 dose | SOC | Published in PR journal | 4.84 | Unknown |
| TOGETHER,18 2021 (Southeast Brazil) | RCT | 1355 | 400 μg/kg to 90 kg of weight daily for 3 d | Placebo | Presentation published online | 3.91 | Unknown |
| Vallejos et al,19 2021 (Argentina) | RCT | 501 | Patients weighing ≤80 kg: 12 mg/d for 2 d; patients weighing 80-110 kg: 18 mg/d for 2 d; patients weighing >110 kg: 24 mg/d for 2 d | SOC | Published in PR journal | 5.14 | 4.8% in experimental group, 4.4% in control group |
Abbreviations: BID, twice daily; I-TECH, Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients; PR, peer-reviewed; RCT, randomized clinical trial; SOC, standard of care; TOGETHER, Early Treatment of COVID-19 With Repurposed Therapies: The TOGETHER Adaptive Platform Trial.